clinical trial · NCT05972044
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
ADHDSolriamfetol 150 mgSolriamfetol 300 mgPlacebo
brief summary
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
started
Jul 6, 2023
primary completion
Feb 7, 2025
completion
Mar 14, 2025
last updated
Feb 10, 2026
detailed description
Eligible subjects must have a primary diagnosis of ADHD based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to be treated with solriamfetol 150 mg, solriamfetol 300 mg, or placebo, once daily for 6 weeks.
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults With ADHD.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol